{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000070","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.906066+00:00","generated_at":"2026-05-16T13:45:06.093823+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Halozyme awards CEO $10M performance-based RSUs tied to stock price targets $115-$170","bullets":["Compensation Committee approved one-time PSU grant for CEO Dr. Helen Torley with $10M target fair value.","Shares vest based on achieving 20-trading-day average stock price of $115 (50%), $130 (100%), $145 (150%), or $170 (200%) over 4-year performance period.","Time-based vesting requires continued employment through fourth anniversary; voluntary resignation/retirement forfeits all performance-vested shares.","Grant intended to retain CEO and incentivize growth and profitability during next stage."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000070","json":"https://secwatch.observer/filing/0001159036-25-000070.json","markdown":"https://secwatch.observer/filing/0001159036-25-000070.md","text":"https://secwatch.observer/filing/0001159036-25-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000070/0001159036-25-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000070/halo-20251204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:45:06.093823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}